{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"87","value":"1.02"},{"groupId":"OG001","spread":"61","value":"1.08"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Intracycle Ra of LY2523355 is the ratio of LY2523355 maximum plasma concentration (Cmax) on Day 3 of Cycle 1 to the Cmax of LY2523355 on Day 1 of Cycle 1 following daily doses of LY2523355 on Days 1, 2 and 3 of Cycle 1 (21-day cycle) at each dose level.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"LY2523355: 5 milligrams/square meter/day (mg/m²/day) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 + pegfilgrastim on Day 4 of each 21-day cycle.","id":"OG000","title":"5 mg/m²LY2523355"},{"description":"LY2523355: 6 mg/m²/day administered intravenously as a one hour infusion on Days 1, 2, and 3 + pegfilgrastim on Day 4 of each 21-day cycle.","id":"OG001","title":"6 mg/m² LY253355"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All enrolled participants who received at least 1 dose of study drug with Ra measure.","reportingStatus":"POSTED","timeFrame":"Day 1 and Day 3 of Cycle 1 (21-day cycle)","title":"Pharmacokinetics, Intracycle Accumulation Ratio (Ra) of LY2523355","type":"SECONDARY","unitOfMeasure":"ratio"}